# Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers

> **NCT02253862** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 17 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tadalafil
- **DRUG:** Tipranavir
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT02253862
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2006-03
- **Final completion:** —
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2014-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02253862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02253862, "Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT02253862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*